Antibody Firm Xencor Exclusively Licenses Xtend Antibody Technology to Merck | GenomeWeb

Xencor said this week it has exclusively licensed its Xtend antibody technology to Merck.

The drug firm will use the technology to develop antibodies against an undisclosed drug target.

In return, Merck will pay Xencor a $3 million upfront license fee. It also will pay Xencor an undisclosed amount if it selects an Xtend variant, and pay undisclosed amounts in clinical development milestones and royalties on product sales.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.